Regen, CheckPoint deal

Regen granted its CheckPoint Immunology Inc. subsidiary an exclusive, worldwide license to develop and commercialize nuclear receptor subfamily 2 group F member 6 (NR2F6; COUP-TFIII) technology for hu...